Clinical trial for improving the quality of life of female patients with stress urinary incontinence treated by long needle penetrating

注册号:

Registration number:

ITMCTR1900002400

最近更新日期:

Date of Last Refreshed on:

2019-06-14

注册时间:

Date of Registration:

2019-06-14

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

“秩边透水道”针法改善女性压力性尿失禁患者生活质量的临床研究

Public title:

Clinical trial for improving the quality of life of female patients with stress urinary incontinence treated by long needle penetrating

注册题目简写:

English Acronym:

研究课题的正式科学名称:

“秩边透水道”针法改善女性压力性尿失禁患者生活质量的临床研究

Scientific title:

Clinical trial for improving the quality of life of female patients with stress urinary incontinence treated by long needle penetrating

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR1900023848 ; ChiMCTR1900002400

申请注册联系人:

王海军

研究负责人:

冀来喜

Applicant:

Haijun Wang

Study leader:

Laixi Ji

申请注册联系人电话:

Applicant telephone:

+86 15803409395

研究负责人电话:

Study leader's telephone:

+86 13509714277

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

whjdavid@163.com

研究负责人电子邮件:

Study leader's E-mail:

tyjilaixi@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

山西省高校园区大学街121号

研究负责人通讯地址:

山西省高校园区大学街121号

Applicant address:

121 Daxue Street, Higher Education Area, Shanxi, China

Study leader's address:

121 Daxue Street, Higher Education Area, Shanxi, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山西中医药大学

Applicant's institution:

Shanxi University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2017LC-18

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

山西中医学院第三中医院医学伦理委员会

Name of the ethic committee:

Ethics Review Committee of the 3rd hospital of Shanxi university of Traditional Chinese Medicin

伦理委员会批准日期:

Date of approved by ethic committee:

2017/9/28 0:00:00

伦理委员会联系人:

张天生

Contact Name of the ethic committee:

Tiansheng Zhang

伦理委员会联系地址:

山西省高校园区大学街121号

Contact Address of the ethic committee:

121 Daxue Street, Higher Education Area, Shanxi, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山西中医药大学

Primary sponsor:

Shanxi University of Chinese Medicine

研究实施负责(组长)单位地址:

山西省高校园区大学街121号

Primary sponsor's address:

121 Daxue Street, Higher Education Area, Shanxi, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山西省

市(区县):

太原市

Country:

China

Province:

Shanxi

City:

Taiyuan

单位(医院):

山西中医药大学

具体地址:

山西省高校园区大学街121号

Institution
hospital:

Shanxi University of Chinese Medicine

Address:

121 Daxue Street, Higher Education Area, Shanxi, China

经费或物资来源:

自筹经费

Source(s) of funding:

self-raised fund

研究疾病:

压力性尿失禁

研究疾病代码:

Target disease:

Stress urinary incontinence

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究旨在通过观察“秩边透水道”针法改善女性压力性尿失禁患者生活质量的影响,以期为压力性尿失禁的临床规范化治疗提供依据,也为临床治疗泌尿系疾病提供借鉴。

Objectives of Study:

To observe the curative effect of "Zhibian(BL54) penetrating Shuidao(ST28)" method on improving quality of life of female people with stress urinary incontinence,and then to provide a basis for clinical standardized treatment of stress urinary incontinence and provide a reference for clinical treatment of urinary system diseases.

药物成份或治疗方案详述:

对照组:中极、膀胱俞、肾俞、三阴交 试验组:“秩边透水道”

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)年龄≧30周岁、≦70周岁、女性; (2)临床诊断为压力性尿失禁; (3)自愿加入本试验,并签署医患沟通同意书,且依从性好、可随访。

Inclusion criteria

(1) Female aged 30 to 70 years; (2) Meet the diagnostic standard of stress urinary incontinence; (3) attending this experiment voluntarily.

排除标准:

(1)合并有其他类型尿失禁者,如混合型尿失禁,充溢性尿失禁,急迫性尿失禁等; (2)合并泌尿系感染者; (3)既往有过盆底手术史或尿失禁手术治疗史, (4)伴有糖尿病、马尾神经病损、脊髓病变等疾病者; (5)长期服用激素者; (6)安装有心脏起搏器或对金属制品敏感者; (7)妊娠或哺乳期患者。 (8)正在参与其它研究课题者; (9)研究人员认为其它原因不适合继续临床试验者。

Exclusion criteria:

(1) with other type of urinary incontinence; (2) combing with urine system infection; (3) with the history of Pelvic reconstructive surgery and SUI surgery; (4) combing with diabetes, cauda equine syndrome and spinal cord problems; (5) taking adrenal hormone related medicine; (6) with peacekeeper or sensitive to mental materials; (7) with pregnancy or in nursing period; (8) attending other trials; (9) other reasons.

研究实施时间:

Study execute time:

From 2017-10-01

To      2018-12-31

征募观察对象时间:

Recruiting time:

From 2017-10-01

To      2018-11-30

干预措施:

Interventions:

组别:

治疗组

样本量:

51

Group:

Experimental group

Sample size:

干预措施:

“秩边透水道”针法

干预措施代码:

Intervention:

Zhibian(BL54) penetrating Shuidao(ST28)" method

Intervention code:

组别:

对照组

样本量:

51

Group:

Control group

Sample size:

干预措施:

中极、膀胱俞、肾俞、三阴交

干预措施代码:

Intervention:

Zhongji, Pangguangsu, Shensu, Shanyinjiao

Intervention code:

样本总量 Total sample size : 102

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

山西省

市(区县):

太原市

Country:

China

Province:

Shanxi

City:

Taiyuan City

单位(医院):

山西医学院第三中医院

单位级别:

三级甲等

Institution/hospital:

the third hospital of Shanxi University of Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

尿失禁生活质量问卷

指标类型:

主要指标

Outcome:

I-QOL

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

72小时排尿日记卡

指标类型:

次要指标

Outcome:

72h urine diary card

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

1小时尿垫试验

指标类型:

次要指标

Outcome:

1 hour pad

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 32
Min age years
最大 69
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

由专门的第三方统计者借助Spss18.0软件进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

the patients were randomly divided into two groups (treatment group and control group) by special man

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过网络平台(中国临床试验注册中心,www.chictr.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表(Case Record Form, CRF)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above